[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100606982":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":15,"centralContacts":19,"locations":25,"responsibleParty":40,"collaborators":10,"id":43,"slug":44,"hasResults":45,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":10,"eligibilityCriteria":49,"healthyVolunteers":45,"sex":50,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":10,"studyType":56,"phases":10,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":65,"whyStopped":10,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":75},{"fullName":5,"class":6},"Firat University","OTHER",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"People Using Anti-TNF-α Medication",null,"20 participants will consist of patients using anti-TNF-α drugs.",{"label":13,"type":10,"description":14,"interventionNames":10},"People Using Non-TNF-α Medication","20 participants will consist of patients using non-TNF-α drugs.",[16],{"name":17,"affiliation":5,"role":18},"Songül BAĞLAN YENTÜR, Doç. Dr.","STUDY_DIRECTOR",[20],{"name":21,"role":22,"phone":23,"phoneExt":10,"email":24},"Ahmet S KORKMAZ","CONTACT","+905425491901","fztseckinkorkmaz@hotmail.com",[26],{"facility":27,"status":10,"city":28,"state":10,"zip":10,"country":29,"countryCode":10,"cosmosGeoPoint":30,"geoPoint":35,"contacts":36},"Fırat University","Elâzığ","Turkey (Türkiye)",{"type":31,"coordinates":32},"Point",[33,34],39.22321,38.67431,{"lat":34,"lon":33},[37],{"name":38,"role":22,"phone":39,"phoneExt":10,"email":24},"Ahmet Seçkin Korkmaz","05425491901",{"type":41,"investigatorFullName":38,"investigatorTitle":42,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Principal Investigator","100606982","investigation-of-the-effects-of-anti-tnf--and-non-tnf--drugs-n-patients-with-rheumatoid-arthritis-100606982",false,"NCT07182630","Investigation Of The Effects Of Anti-Tnf-Α And Non-Tnf-Α Drugs İn Patients With Rheumatoid Arthritis","Investigation Of The Effects Of Anti-Tnf-Α And Non-Tnf-Α Drugs On Aerobic Capacity, Muscle Strength, Fatigue, Cardiovascular Disease Risk Factors, And Disease Activity İn Patients With Rheumatoid Arthritis","Inclusion Criteria:\n\n* Diagnosed with RA according to the 2010 American College of Rheumatology (ACR-2010) criteria\n* Be between 18 and 65 years of age\n* Be literate\n* Have been using one of the anti-TNF-α or non-TNF-α drugs for a period of 1-3 years\n\nExclusion Criteria:\n\n* Being pregnant or having a diagnosis of malignancy\n* Having a dysfunction that would limit physical activity (cycling for aerobic capacity assessment), such as severe neurological involvement, immobility, or incooperation\n* Having a regular exercise habit (reporting a habit of exercising 3 or more days per week)\n* Having another chronic disease\n* Having cardiac symptoms according to the New York Heart Association\n* Having mental problems that prevent participation in assessments","FEMALE","18 Years","65 Years",{"count":54,"type":55},40,"ESTIMATED","OBSERVATIONAL","In RA, joint structure is damaged due to destructive inflammation in the synovium. This condition negatively affects the patient's level of physical activity. As the patient becomes more immobile, their muscle mass and strength decrease and their aerobic capacity declines. One of the drug groups used in the pharmacological treatment of RA is anti-TNF-α drugs. The aim of this study is to investigate the effects of anti-TNF-α and non-TNF-α drug treatments on aerobic capacity, muscle strength, fatigue, cardiorespiratory risk factors, and disease activity in RA patients.",[59],"Rheumatoid Arthritis (RA",[61,62,63,64],"Anti TNF-α","Non TNF-α","Rheumatoid arthritis","Aerobic Capacity","NOT_YET_RECRUITING","2025-09-18",{"date":68,"type":69},"2025-09-19","ACTUAL",{"date":71,"type":55},"2025-10-01",{"date":73,"type":55},"2026-01-30",{"name":5,"class":6},1]